The purpose of this study is to determine the beneficial effect of n-acetylcysteine (NAC), an
inhaled medication that breaks down mucus, on lung function. NAC is a medication approved by
the US Food and Drug Administration (FDA) for the treatment of chronic diseases of the
respiratory system, including asthma. With CT lung imaging, the investigators seek to
identify a subgroup of patients with asthma with a 'mucus' profile. This is a single-arm
study which means all participants will receive the same treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)